Formulation

Formulation


Monash University’s Medicines Manufacturing Innovation Centre (MMIC) is in Australia’s word-class biotechnology and medical research precinct in Victoria.

Established in 2017, MMIC is an initiative between the Victorian State Government and Monash Institute of Pharmaceutical Sciences (MIPS). MMIC provides pharmaceutical and medical technology companies, and allied industries, support through a dedicated team of experienced pharmaceutical scientists who work in partnership with industry clients to develop new product formulations, resolve manufacturing process challenges, and supply highly skilled, industry-ready candidates for the workforce.

Woke and MMIC entered a partnership in October 2021. With Woke Pharmaceuticals, MMIC is developing proprietary formulations of psilocybin. The first drug candidate, WP001, is a novel rapid release capsule at a dose per capsule of 1mg, for the treatment of moderate depression. The second drug candidate, WP002, is a novel rapid release tablet at a dose per capsule of 25mg, for the treatment of treatment-resistant depression.


“Monash’s MMIC have world-leading capabilities to formulate novel dosage forms and provide IP protection for our formulations.”